Gelion PLC (AIM:GELN, OTC:GELNF, FRA:X0S) shares rose over 12% to 18p after it reported £9.6 million of pro forma cash and no debt. Releasing full-year results, it noted agreements with two major automakers, and the CEO says it's moving from validation towards customer programmes and scale-up.
CelLBxHealth PLC (AIM:CLBX, FRA:DWV) has signed a deal with a Swiss biotech to support a radiopharmaceutical clinical study, its first move into that market. It's also targeting £3 million to £4 million of revenue in 2027, more than double its expected 2026 turnover.
Ashtead Technology Holdings PLC (AIM:AT.) has agreed a recommended £505 million cash takeover by US private equity firm Ember Infrastructure Management. The 615p per share offer is an 81% premium to its pre-offer price, and completion is expected late this year or early 2027.
Rainbow Rare Earths Ltd (LSE:RBW, OTC:RBWRF, FRA:RR1) calls 2026 a "defining period" as the West moves to secure rare earths outside China. Cash rose to $12.9 million, with the Phalaborwa pre-feasibility study due in Q4 and a definitive feasibility study in the first half of 2027.
Bradda Head Lithium Ltd (AIM:BHL) has lifted its cash to $2.57 million after its July fundraise. Early drilling at Whistlejacket, in partnership with Rio Tinto's Kennecott, returned 31.8 metres at 1.07% lithium oxide, and it's also eyeing uranium licences in Tanzania.
Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.
